Inhibitor Therapeutics (INTI) Free Cash Flow (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Free Cash Flow came in at -$1.1 million in Q1 2026, up 15.6% YoY from -$938162.5 in Q1 2025, and down 90.33% on a QoQ basis from -$569795.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Free Cash Flow (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Free Cash Flow data on file, last reported at -$1.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 15.6% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.0 million (up 10.73% YoY) and the FY2025 annual result came in at -$3.2 million, up 1.02% from the prior year.
- Free Cash Flow declined to -$1.1 million in Q1 2026, from -$569795.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $11.9 million in Q4 2022 to a low of -$1.3 million in Q1 2025.
- A 5-year average of $89571.9 and a median of -$682614.0 in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 52605.04% — and 2023, when it tumbled 1613.78%.
- Tracing INTI's Free Cash Flow over 5 years: stood at $11.9 million in 2022, then plunged by 105.86% to -$697706.0 in 2023, then decreased by 10.57% to -$771441.0 in 2024, then gained by 26.14% to -$569795.0 in 2025, then plunged by 90.33% to -$1.1 million in 2026.
- The last three Free Cash Flow figures came in at -$1.1 million (Q1 2026), -$569795.0 (Q4 2025), and -$761245.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.08 Mn |
| Mar 31, 2026 | -1.08 Mn |
| Dec 31, 2025 | -569,795.00 |
| Dec 31, 2025 | -569,795.00 |
| Sep 30, 2025 | -761,245.00 |
| Sep 30, 2025 | -761,245.00 |
| Jun 30, 2025 | -583,991.00 |
| Jun 30, 2025 | -583,991.00 |
| Mar 31, 2025 | -1.28 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | -771,441.00 |
| Dec 31, 2024 | -771,441.00 |
| Sep 30, 2024 | -720,438.00 |
| Sep 30, 2024 | -720,438.00 |
| Jun 30, 2024 | -583,079.00 |
| Jun 30, 2024 | -583,079.00 |
| Mar 31, 2024 | -1.16 Mn |
| Mar 31, 2024 | -1.16 Mn |
| Dec 31, 2023 | -697,706.00 |
| Dec 31, 2023 | -697,706.00 |